Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itolizumab - Biocon/Equillium

Drug Profile

Itolizumab - Biocon/Equillium

Alternative Names: Alzumab; Anti-CD6 monoclonal antibody - Biocon/CIMAB; Anti-CD6 monoclonal antibody h-T1; Anti-CD6-monoclonal-antibody-Biocon; Bmab600; EQ-001; h T1; Humanised anti-CD6 monoclonal antibody ior t1; T12 antibody; T12 monoclonal antibody; T1h; T1hT

Latest Information Update: 10 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Biocon; Biotech Pharmaceutical; Equillium
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD6 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Phase II Rheumatoid arthritis
  • Phase I/II Graft-versus-host disease
  • Phase I Asthma; Lupus nephritis
  • No development reported Autoimmune disorders; Multiple sclerosis; Psoriasis

Most Recent Events

  • 01 Oct 2019 Phase-I clinical trials in Lupus nephritis in USA (SC) (NCT04128579)
  • 20 Jun 2019 Phase-I clinical trials in Asthma in New Zealand (SC) after June 2019 (NCT04007198)
  • 20 Jun 2019 Phase-I clinical trials in Asthma in Australia (SC) (NCT04007198)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top